“…1 Since 2005, the next-generation sequencing (NGS) technologies 2 have allowed us to better understand the molecular classification of cancer, which may provide benefits for clinical practice in oncology, such as diagnosis, prognosis, and treatment decisions. Going along with proteomics in the clinical and biological applications, 3 The Cancer Genome Atlas (TCGA) has performed a lot of sequencing analysis, including whole exome sequencing, transcriptome profiling, and DNA methylation analysis. In prostate cancer, the TCGA was presented with a comprehensive molecular analysis of 333 primary prostate cancer, 4 which revealed a molecular taxonomy with seven different subtypes, such as specific gene fusions (erythroblast transformation specific (ETS) family of transcription factors), or mutations (speckletype POZ protein (SPOP), forkhead box protein A1 ALDH1A3 correlates with luminal phenotype in prostate cancer (FOXA1)).…”